Bank of New York Mellon Corp Sells 49,932 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Bank of New York Mellon Corp reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 18.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 226,299 shares of the company’s stock after selling 49,932 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.26% of IDEAYA Biosciences worth $5,816,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. State Street Corp boosted its stake in shares of IDEAYA Biosciences by 15.4% in the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock valued at $105,112,000 after purchasing an additional 443,640 shares during the last quarter. Barclays PLC boosted its stake in shares of IDEAYA Biosciences by 188.8% in the 3rd quarter. Barclays PLC now owns 181,170 shares of the company’s stock valued at $5,739,000 after purchasing an additional 118,438 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of IDEAYA Biosciences by 12.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 689,073 shares of the company’s stock valued at $21,830,000 after purchasing an additional 78,518 shares during the last quarter. Verition Fund Management LLC bought a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at $246,000. Finally, Jennison Associates LLC boosted its stake in shares of IDEAYA Biosciences by 136.6% in the 3rd quarter. Jennison Associates LLC now owns 972,266 shares of the company’s stock valued at $30,801,000 after purchasing an additional 561,404 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IDYA has been the topic of several research analyst reports. Stephens reissued an “overweight” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Wedbush reissued an “outperform” rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $53.58.

IDEAYA Biosciences Trading Down 2.0 %

IDYA opened at $18.58 on Monday. The company’s fifty day moving average price is $21.95 and its two-hundred day moving average price is $27.15. IDEAYA Biosciences, Inc. has a 1-year low of $16.95 and a 1-year high of $46.40. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -5.63 and a beta of 0.76.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $7.00 million. As a group, equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.